| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -1,726,899 |
| Amortization and depreciation | 53,202 |
| Share-based compensation | 20,205 |
| Amortization of right-of-use assets | 103,478 |
| Unrealized foreign exchange loss | -1,358 |
| Inventories | -70,366 |
| Prepaids and other currents assets | -129,992 |
| Accounts receivable | -122,160 |
| Accounts payable and accrued liabilities | -274,066 |
| Lease obligations | -107,412 |
| Total cash used in operating activities | -1,607,616 |
| Share issuance costs | 137,178 |
| Total cash (used in) provided by financing activities | -137,178 |
| Decrease in cash and cash equivalents during the period | -1,744,794 |
| Cash and cash equivalents at beginning of period | 11,075,871 |
| Cash and cash equivalents at end of period | 9,331,077 |
InMed Pharmaceuticals Inc. (INM)
InMed Pharmaceuticals Inc. (INM)